Endocrine Testing Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

The endocrine system is a very complex network that consists of several glands located throughout the body. Endocrine diagnostics test to measure the level of various hormones in a human body. It is also used to identify whether the endocrine glands are working properly. An optimally functioning endocrine system is essential to restoring and maintaining health.

Globally, the endocrine testing market has been accelerated on account of the rapid growth global geriatric population in both developed and developing countries. The changing lifestyles, increasing stress, and unhealthy food habits result in increased obesity and disturbed hormonal changes, which contributed substantially towards the growth of the endocrine diagnostics market. Moreover, increasing health awareness coupled with the government initiatives facilitated early diagnosis of endocrine disorders, which is expected to propel the demand for endocrine test kits. However, the high cost of technology is expected to be the major restraint for the growth of the endocrine testing market. Nonetheless, investment in research and technology is considered as a major opportunity for the growth of the global endocrine testing market.

The endocrine testing market can be segmented on the basis of test such as Dehydroepiandrosterone sulfate (DHEAS), Progesterone, Luteinizing Hormone (LH), Estradiol (E2), Human Chorionic Gonadotropin (hCG), Follicle Stimulating (FSH), testosterone, thyroid prolactin, Thyroid Stimulating Hormone (TSH), cortisol, insulin, and other tests such as gastrin, thymosin, and secretin tests. Thyroid stimulating hormone (TSH) was the leading segment owing to rising incidences of thyroid disorders and the growing awareness about the correlation between variations in the thyroid hormones levels and cardiovascular disorders. Insulin test is expected to witness the fastest growth in the years to come. This growth is mainly due to increase the rate of diabetes patients across the globe.

On the basis of technology, the market can be segmented into monoclonal & polyclonal antibody technologies, tandem mass spectrometry, immunoassay, sensors, clinical chemistry technologies, and others. Tandem mass spectrometry is expected to show significant growth in the years to come. Mass spectroscopy analysis is the most recent developed technology. The sensitivity of the tests by mass spectroscopy technology is very high.

Some of the key end-users include commercial laboratories, home-based tests, ambulatory care centers, hospitals and other healthcare settings. The commercial laboratories were the largest segment due to advanced infrastructure coupled with skilled personnel. The home-based test segment is growing fast with the introduction of new user-friendly and cost-effective diagnostic kits. This is expected to increase the penetration of home-based tests.

North America is projected to be the largest revenue contributing region. North America is expected to remain the dominant region over the next few years. Asia-Pacific is projected to be the fastest-growing region in the endocrine testing market during the forecast period as a result of demand from developing economies such as China and India. As a result of increasing aging population and increasing health awareness in Brazil, Latin America is also expected to experience significant growth in the years to come.

Some of the key players operating into this market include Bio Rad Laboratories, DiaSorin, Hoffmann-La Roche Ltd., LabCorp, Quest Diagnostics, Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies and bioMerieux SA.